Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept

Abstract Background In de novo kidney transplant recipients (KTR) treatment with belatacept has been established as a comparable option as maintenance immunosuppression, preferably as a strategy to convert from calcineurin inhibitor (CNI)- to belatacept-based immunosuppression. Switch to belatacept...

Full description

Bibliographic Details
Main Authors: Mira Choi, Friederike Bachmann, Kaiyin Wu, Nils Lachmann, Danilo Schmidt, Susanne Brakemeier, Michael Duerr, Andreas Kahl, Kai-Uwe Eckardt, Klemens Budde, Peter Nickel
Format: Article
Language:English
Published: BMC 2020-08-01
Series:BMC Nephrology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12882-020-01992-6